COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review
Introduction: The proliferation of literature regarding the COVID-19 pandemic has served to highlight a wide spectrum of disease manifestations and complications, such as thrombotic microangiopathies. Our review with a brief case presentation highlights the increasing recognition of TTP in COVID-19...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Hematology Reports |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2038-8330/14/3/35 |
| _version_ | 1797487705013092352 |
|---|---|
| author | Haseeb Chaudhary Usama Nasir Khezar Syed Maria Labra Christopher Reggio Ansar Aziz Parin Shah Roopika Reddy Navdeep Sangha |
| author_facet | Haseeb Chaudhary Usama Nasir Khezar Syed Maria Labra Christopher Reggio Ansar Aziz Parin Shah Roopika Reddy Navdeep Sangha |
| author_sort | Haseeb Chaudhary |
| collection | DOAJ |
| description | Introduction: The proliferation of literature regarding the COVID-19 pandemic has served to highlight a wide spectrum of disease manifestations and complications, such as thrombotic microangiopathies. Our review with a brief case presentation highlights the increasing recognition of TTP in COVID-19 and describes its salient characteristics. Methods: We screened the available literature in PubMed, EMBASE, and Cochrane databases from inception until April 2022 of articles mentioning COVID-19-associated TTP in English language. Results: From 404 records, we included 8 articles mentioning data of 11 patients in our review. TTP was predominantly reported in females (72%) with a mean age of 48.2 years (SD 15.1). Dyspnea was the most common symptom in one third of patients (36.6%). Neurological symptoms were reported in 27.3% of cases. The time to diagnosis of TTP was 10 days (SD 5.8) from onset of COVID-19. All 11 cases underwent plasma exchange (PLEX), with a mean of 12 sessions per patient, whereas 6 cases received Rituximab (54.5%), and 3 received Caplacizumab (27.3%). One patient died from the illness. Conclusion: This review of available literature highlights the atypical and refractory nature of COVID-19-associated TTP. It required longer sessions of PLEX, with half of the patients receiving at least one immunosuppressant. |
| first_indexed | 2024-03-09T23:52:35Z |
| format | Article |
| id | doaj.art-5cd2ed73b7034ede8a36da9feca36c05 |
| institution | Directory Open Access Journal |
| issn | 2038-8330 |
| language | English |
| last_indexed | 2024-03-09T23:52:35Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hematology Reports |
| spelling | doaj.art-5cd2ed73b7034ede8a36da9feca36c052023-11-23T16:31:41ZengMDPI AGHematology Reports2038-83302022-08-0114325326010.3390/hematolrep14030035COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic ReviewHaseeb Chaudhary0Usama Nasir1Khezar Syed2Maria Labra3Christopher Reggio4Ansar Aziz5Parin Shah6Roopika Reddy7Navdeep Sangha8Department of Internal Medicine, Reading Hospital, Reading, PA 19611, USADepartment of Internal Medicine, Reading Hospital, Reading, PA 19611, USADepartment of Internal Medicine, Reading Hospital, Reading, PA 19611, USADepartment of Internal Medicine, Reading Hospital, Reading, PA 19611, USADepartment of Internal Medicine, Reading Hospital, Reading, PA 19611, USADepartment of Hospital Medicine, Reading Hospital, Reading, PA 19611, USADepartment of Pulmonary and Critical Care, Reading Hospital, Reading, PA 19611, USADepartment of Pulmonary and Critical Care, Reading Hospital, Reading, PA 19611, USADepartment of Hematology and Oncology, Reading Hospital, Reading, PA 19611, USAIntroduction: The proliferation of literature regarding the COVID-19 pandemic has served to highlight a wide spectrum of disease manifestations and complications, such as thrombotic microangiopathies. Our review with a brief case presentation highlights the increasing recognition of TTP in COVID-19 and describes its salient characteristics. Methods: We screened the available literature in PubMed, EMBASE, and Cochrane databases from inception until April 2022 of articles mentioning COVID-19-associated TTP in English language. Results: From 404 records, we included 8 articles mentioning data of 11 patients in our review. TTP was predominantly reported in females (72%) with a mean age of 48.2 years (SD 15.1). Dyspnea was the most common symptom in one third of patients (36.6%). Neurological symptoms were reported in 27.3% of cases. The time to diagnosis of TTP was 10 days (SD 5.8) from onset of COVID-19. All 11 cases underwent plasma exchange (PLEX), with a mean of 12 sessions per patient, whereas 6 cases received Rituximab (54.5%), and 3 received Caplacizumab (27.3%). One patient died from the illness. Conclusion: This review of available literature highlights the atypical and refractory nature of COVID-19-associated TTP. It required longer sessions of PLEX, with half of the patients receiving at least one immunosuppressant.https://www.mdpi.com/2038-8330/14/3/35SARS-CoV-2COVID-19TTPrefractorythrombotic microangiopathies |
| spellingShingle | Haseeb Chaudhary Usama Nasir Khezar Syed Maria Labra Christopher Reggio Ansar Aziz Parin Shah Roopika Reddy Navdeep Sangha COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review Hematology Reports SARS-CoV-2 COVID-19 TTP refractory thrombotic microangiopathies |
| title | COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review |
| title_full | COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review |
| title_fullStr | COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review |
| title_full_unstemmed | COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review |
| title_short | COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review |
| title_sort | covid 19 associated thrombotic thrombocytopenic purpura a case report and systematic review |
| topic | SARS-CoV-2 COVID-19 TTP refractory thrombotic microangiopathies |
| url | https://www.mdpi.com/2038-8330/14/3/35 |
| work_keys_str_mv | AT haseebchaudhary covid19associatedthromboticthrombocytopenicpurpuraacasereportandsystematicreview AT usamanasir covid19associatedthromboticthrombocytopenicpurpuraacasereportandsystematicreview AT khezarsyed covid19associatedthromboticthrombocytopenicpurpuraacasereportandsystematicreview AT marialabra covid19associatedthromboticthrombocytopenicpurpuraacasereportandsystematicreview AT christopherreggio covid19associatedthromboticthrombocytopenicpurpuraacasereportandsystematicreview AT ansaraziz covid19associatedthromboticthrombocytopenicpurpuraacasereportandsystematicreview AT parinshah covid19associatedthromboticthrombocytopenicpurpuraacasereportandsystematicreview AT roopikareddy covid19associatedthromboticthrombocytopenicpurpuraacasereportandsystematicreview AT navdeepsangha covid19associatedthromboticthrombocytopenicpurpuraacasereportandsystematicreview |